BRPI1009757A2 - composto, composição farmacêutica, e , uso de um composto. - Google Patents

composto, composição farmacêutica, e , uso de um composto.

Info

Publication number
BRPI1009757A2
BRPI1009757A2 BRPI1009757A BRPI1009757A BRPI1009757A2 BR PI1009757 A2 BRPI1009757 A2 BR PI1009757A2 BR PI1009757 A BRPI1009757 A BR PI1009757A BR PI1009757 A BRPI1009757 A BR PI1009757A BR PI1009757 A2 BRPI1009757 A2 BR PI1009757A2
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutical composition
pharmaceutical
composition
Prior art date
Application number
BRPI1009757A
Other languages
English (en)
Inventor
Kouacou Adiey
Laxminarayan Bhat
Prabhu Prasad Mohapatra
Original Assignee
Reviva Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reviva Pharmaceuticals Inc filed Critical Reviva Pharmaceuticals Inc
Publication of BRPI1009757A2 publication Critical patent/BRPI1009757A2/pt
Publication of BRPI1009757B1 publication Critical patent/BRPI1009757B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/341,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/361,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/5381,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
BRPI1009757A 2009-02-26 2010-02-26 composto derivado de arilpiperazina útil no tratamento de psicose, esquizofrenia, mania aguda, distúrbio bipolar, distúrbio autista ou depressão, composição farmacêutica, e, uso da mesma BRPI1009757B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15579109P 2009-02-26 2009-02-26
PCT/US2010/025687 WO2010099502A1 (en) 2009-02-26 2010-02-26 Compositions, synthesis, and methods of utilizing arylpiperazine derivatives

Publications (2)

Publication Number Publication Date
BRPI1009757A2 true BRPI1009757A2 (pt) 2016-03-15
BRPI1009757B1 BRPI1009757B1 (pt) 2020-01-14

Family

ID=42631516

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1009757A BRPI1009757B1 (pt) 2009-02-26 2010-02-26 composto derivado de arilpiperazina útil no tratamento de psicose, esquizofrenia, mania aguda, distúrbio bipolar, distúrbio autista ou depressão, composição farmacêutica, e, uso da mesma

Country Status (25)

Country Link
US (9) US8188076B2 (pt)
EP (1) EP2400968B1 (pt)
JP (1) JP5337259B2 (pt)
KR (1) KR101705727B1 (pt)
CN (2) CN106045936A (pt)
AU (1) AU2010217772B2 (pt)
BR (1) BRPI1009757B1 (pt)
CA (1) CA2753599C (pt)
CO (1) CO6430428A2 (pt)
DK (1) DK2400968T3 (pt)
ES (1) ES2605232T3 (pt)
HK (1) HK1167240A1 (pt)
HU (1) HUE031053T2 (pt)
IL (1) IL214754A (pt)
MX (1) MX2011008885A (pt)
MY (1) MY161473A (pt)
NZ (1) NZ595263A (pt)
PH (1) PH12011501669B1 (pt)
PL (1) PL2400968T3 (pt)
PT (1) PT2400968T (pt)
RU (1) RU2506262C2 (pt)
SG (1) SG173842A1 (pt)
UA (1) UA102730C2 (pt)
WO (2) WO2010099502A1 (pt)
ZA (1) ZA201106805B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106045936A (zh) 2009-02-26 2016-10-26 雷维瓦药品公司 芳基哌嗪衍生物、含有该衍生物的组合物及其制药用途
KR101571670B1 (ko) * 2012-08-08 2015-11-25 주식회사 씨엠지제약 아리피프라졸을 포함하는 경구용 속용 필름 제제
WO2015157451A1 (en) 2014-04-08 2015-10-15 Reviva Pharmaceuticals, Inc. Methods for treating attention deficit hyperactivity disorder
JP2018502158A (ja) * 2015-01-12 2018-01-25 レビバ ファーマシューティカルズ,インコーポレイティド パーキンソン病と関連する精神病の治療方法
JP2018502157A (ja) 2015-01-12 2018-01-25 レビバ ファーマシューティカルズ,インコーポレイティド アルツハイマー病の治療方法
WO2016115039A1 (en) 2015-01-12 2016-07-21 Reviva Pharmaceuticals Inc. Methods for treating pulmonary hypertension
GB201508864D0 (en) * 2015-05-22 2015-07-01 Glaxosmithkline Ip Dev Ltd Compounds
WO2017042837A2 (en) * 2015-09-11 2017-03-16 Sun Pharmaceutical Industries Limited Stable crystalline form of regadenoson
PL3486242T3 (pl) 2016-08-31 2022-03-21 Jiangsu Hengrui Medicine Co. Ltd. Pochodna oksopikolinamidu, sposób jej wytwarzania i zastosowanie farmaceutyczne
CN112618580A (zh) * 2020-12-30 2021-04-09 北京科拓恒通生物技术股份有限公司 鼠李糖乳杆菌Probio-M9及其制品用于制备治疗自闭症药物的用途

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3274194A (en) * 1963-03-29 1966-09-20 Miles Lab Quinazolinedione derivatives
FR2035749A1 (pt) * 1969-02-06 1970-12-24 Bellon Labor Sa Roger
US3726979A (en) * 1971-04-09 1973-04-10 E Hong Method of producing serotonin antagonism
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3879393A (en) * 1973-06-18 1975-04-22 Miles Lab Derivatives of 1,3-disubstituted 2,4(1h,3h)-quinazolinediones
PH17194A (en) * 1980-03-06 1984-06-19 Otsuka Pharma Co Ltd Novel carbostyril derivatives,and pharmaceutical composition containing the same
JPS58159480A (ja) * 1982-03-17 1983-09-21 Chugai Pharmaceut Co Ltd 新規なフエニルピペラジン誘導体
JPS5970675A (ja) * 1982-10-15 1984-04-21 Otsuka Pharmaceut Co Ltd ベンゾオキサジン誘導体
JPS60169467A (ja) 1984-02-10 1985-09-02 Chugai Pharmaceut Co Ltd 新規なフエニルピペラジン誘導体
US4613598A (en) * 1984-03-13 1986-09-23 Mitsubishi Chemical Industries Limited Piperazine derivatives and their acid addition salts
US4716161A (en) 1984-04-17 1987-12-29 Mitsubishi Chemical Industries Limited Phenylpiperazine derivatives and their acid addition salts
US4711883A (en) * 1985-09-30 1987-12-08 Ortho Pharmaceutical Corporation Substituted 3-(4-phenyl-1-piperazinyl)alkylquinazolin-2,4-(1H,3H) diones, methods of preparation, compositions and method of use
DK588486A (da) * 1985-12-09 1987-06-10 Otsuka Pharma Co Ltd Anvendelse af en forbindelse til behandling af hypoxi
US4803203A (en) * 1986-11-05 1989-02-07 Warner-Lambert Company Phenyl and heterocyclic piperazinyl alkoxy-benzheterocyclic compounds as antipsychotic agents
FR2618437B1 (fr) * 1987-07-23 1989-11-17 Rhone Poulenc Sante Nouveaux derives du benzopyranne, leur preparation et les medicaments qui les contiennent
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
DK203990D0 (da) * 1990-08-24 1990-08-24 Novo Nordisk As Piperazinylderivater
US5234924A (en) * 1990-09-26 1993-08-10 Adir Et Compagnie Benzothiazine and benzothiazole compounds useful as analgesics
US5698155A (en) * 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
FR2680172B1 (fr) * 1991-08-05 1993-11-19 Fabre Medicament Pierre Nouvelles piperazinylalcoyl-3 dihydro-2,3 4h-benzoxazine-1,3 ones-4 substituees, leur preparation et leur application en therapeutique.
JPH05331151A (ja) 1992-05-28 1993-12-14 Kyowa Hakko Kogyo Co Ltd キノキサリン−2−オン誘導体
US5994542A (en) * 1995-11-14 1999-11-30 Sumitomo Chemical Company, Limited Process for producing 1-substituted tetrahydroquinazolines
FR2755690B1 (fr) * 1996-11-08 1998-12-18 Adir Nouveaux derives aminomethyl heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE19743435A1 (de) 1997-10-01 1999-04-08 Merck Patent Gmbh Benzamidinderivate
SE0200301D0 (sv) * 2002-02-01 2002-02-01 Axon Biochemicals Bv Thio-carbostyril derivative
BR0305500A (pt) 2003-01-09 2004-11-03 Otsuka Pharma Co Ltd Processo para preparar aripiprazol
CA2428237C (en) 2003-05-08 2010-07-20 Delmar Chemicals Inc. Process for the preparation of carbostyril derivatives
CN102166359A (zh) * 2003-05-23 2011-08-31 大塚制药株式会社 用于治疗情感障碍的喹诺酮衍生物和情绪稳定剂
US7160888B2 (en) * 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
WO2005092841A1 (en) * 2004-03-23 2005-10-06 Pfizer Limited Compounds having beta-agonist activity
US7253168B2 (en) * 2004-04-07 2007-08-07 Neurogen Corporation Substituted 1-benzyl-4-substituted piperazine analogues
US20090198059A1 (en) 2004-09-13 2009-08-06 Chava Satyanarayana Process for the preparation of polymorphs, solvates of aripiprazole using aripirazole acid salts
JP2007137818A (ja) 2005-11-17 2007-06-07 Taisho Pharmaceut Co Ltd 8−ヒドロキシ−2,4(1h,3h)−キナゾリンジオン誘導体
EP2063893A2 (en) * 2006-08-24 2009-06-03 Concert Pharmaceuticals Inc. 3,4-dihydro-2 (1h) - quinolinone and 2 (1h)-quinolinone derivatives
JP4785881B2 (ja) * 2007-02-27 2011-10-05 大塚製薬株式会社 医薬
JP5466147B2 (ja) * 2007-05-21 2014-04-09 レビバ ファーマシューティカルズ,インコーポレーテッド キノリノン系非定型抗精神病薬剤の組成物、合成、及び使用方法
US8642660B2 (en) * 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
EP2234555B1 (en) * 2008-01-25 2016-01-06 Medtronic ATS Medical, Inc. Cryoprobe clamp having transmurality assessment window
WO2009154993A1 (en) * 2008-05-27 2009-12-23 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using piperazine based antipsychotic agents
CN106045936A (zh) * 2009-02-26 2016-10-26 雷维瓦药品公司 芳基哌嗪衍生物、含有该衍生物的组合物及其制药用途
JP5331151B2 (ja) 2011-03-30 2013-10-30 日本発條株式会社 車両用シート

Also Published As

Publication number Publication date
US20170327477A1 (en) 2017-11-16
US8188076B2 (en) 2012-05-29
MX2011008885A (es) 2011-09-29
BRPI1009757B1 (pt) 2020-01-14
EP2400968B1 (en) 2016-09-28
US20160229821A1 (en) 2016-08-11
CN102413830A (zh) 2012-04-11
CA2753599C (en) 2017-03-14
IL214754A0 (en) 2011-11-30
EP2400968A4 (en) 2012-08-01
IL214754A (en) 2014-05-28
HUE031053T2 (en) 2017-06-28
US20140155392A1 (en) 2014-06-05
US8859552B2 (en) 2014-10-14
PL2400968T3 (pl) 2017-04-28
US8461154B2 (en) 2013-06-11
US8980883B2 (en) 2015-03-17
JP5337259B2 (ja) 2013-11-06
PT2400968T (pt) 2016-12-09
MY161473A (en) 2017-04-14
US20100216783A1 (en) 2010-08-26
CO6430428A2 (es) 2012-04-30
AU2010217772A1 (en) 2011-10-20
CN106045936A (zh) 2016-10-26
US20100222359A1 (en) 2010-09-02
KR20120013306A (ko) 2012-02-14
US8431570B2 (en) 2013-04-30
PH12011501669B1 (en) 2014-02-13
KR101705727B1 (ko) 2017-02-10
JP2012519182A (ja) 2012-08-23
US9255076B2 (en) 2016-02-09
RU2011139154A (ru) 2013-04-10
RU2506262C2 (ru) 2014-02-10
US20150005298A1 (en) 2015-01-01
US9604944B2 (en) 2017-03-28
EP2400968A1 (en) 2012-01-04
NZ595263A (en) 2013-06-28
WO2010099502A1 (en) 2010-09-02
US20150166493A1 (en) 2015-06-18
US8575185B2 (en) 2013-11-05
AU2010217772B2 (en) 2014-10-23
ZA201106805B (en) 2013-02-27
DK2400968T3 (da) 2017-01-02
UA102730C2 (uk) 2013-08-12
US20120220579A1 (en) 2012-08-30
SG173842A1 (en) 2011-09-29
CA2753599A1 (en) 2010-09-02
ES2605232T3 (es) 2017-03-13
HK1167240A1 (zh) 2012-11-23
WO2010099503A1 (en) 2010-09-02
US20120220574A1 (en) 2012-08-30
US9975862B2 (en) 2018-05-22

Similar Documents

Publication Publication Date Title
BRPI1007018A2 (pt) composto, composição farmacêutica, e , uso de um composto.
BRPI1008906A2 (pt) composto, composição farmacêutica, e, uso de um composto.
BRPI1008793A2 (pt) composto, uso de um composto, e, composição farmacêutica
BRPI1016219A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0919942A2 (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0907562A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0921375A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0815709A2 (pt) composro, composição farmacêutica, e, uso de um composto.
BR112013008259A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI1008498A2 (pt) Composto, prodroga do composto, medicamento, e, uso de um composto.
BRPI0810696A2 (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0921879A2 (pt) composto, composição farmacêutica , e, uso de um composto
BR112013015397A2 (pt) composto, composição farmacêutica, e, uso de um composto
BR112012004335A2 (pt) composto, composição farmacêutica, e, uso do composto.
BRPI1012892A2 (pt) composto, e, composição farmacêutica.
BRPI0917579A2 (pt) composto, composição farmacêutica, métodos, e, uso de um composto
BRPI0810161A2 (pt) Composto, preparação farmacêutica, composição farmacêutica, e, uso de um composto
BRPI0915134A2 (pt) composto, e, uso de um composto
BR112012031226A2 (pt) composto, uso do composto, composição farmacêutica, e uso de composição farmacêutica
BRPI1009757A2 (pt) composto, composição farmacêutica, e , uso de um composto.
BRPI0906937A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0810019A2 (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0915473A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0919165A2 (pt) composição farmacêutica,e, uso de um composto
BRPI1007186A2 (pt) composto, composição farmacêutica, e, uso de um composto

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/02/2010, OBSERVADAS AS CONDICOES LEGAIS.